2007.06.01 GAP OPEN NVAX DDSS

Pre-market:

NVAX - 15% gap pre marketben...

"Very low doses of Novavax Inc.'s pandemic influenza vaccine provided protection against a lethal challenge of live H5N1 viruses, according to pre-clinical data presented here today at the Second International Conference on Avian Influenza in Humans.

The data show that two 0.6 microgram doses of Novavax's virus-like particle (VLP) H5N1 vaccine -- without the addition of an adjuvant -- protected ferrets from challenges with live H5N1 bird flu viruses. This dose is 25 fold lower than the average human dose for most seasonal flu vaccines and more than 100 times lower than other H5N1 vaccines against avian influenza. Novavax plans to submit an investigational new drug application to the U.S. Food and Drug Administration in mid-2007 to commence human clinical trials with the novel H5N1 influenza vaccine."

Market open:

DDSS figyelem...

Erőteljesen rácuppant a 3 dolláros vonalra...

DDSS napi max. áttörése környékén...

Haszontalan vízszintes vonal maradt mindvégig...

Market closed